More consolidation didn't boost sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve.
Jerry Cacciotti
Advertisement
Articles by Jerry Cacciotti
The disease profiles pharma companies pursue should shape the business models that enable them to grow.
Advertisement
Latest Updated Articles
Pharm Exec 50: Growth from the Bottom UpPublished: May 1st 2012 | Updated: November 25th 2020
Pharma's Next Top Model: Slimmer Business ModelsPublished: March 1st 2006 | Updated: November 15th 2020
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Leading in the Psychedelic Space: Q&A with Tarek Rabah
3
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
4
FDA Approves Hernexeos Under National Priority Voucher Program
5